Abstract
Background: Vanuatu was validated for elimination of lymphatic filariasis (LF) as a public health problem in 2016 and of trachoma in 2022, yet yaws remains endemic. Post-validation surveillance is poorly defined and disease-specific surveys costly. We assessed a multiplex serological platform embedded in prevalence surveys integrated with mass drug administration (MDA) using ivermectin, azithromycin and albendazole, as post-validation surveillance for trachoma and LF and to identify yaws transmission foci.Methods: Six cross-sectional surveys (2021–2024) in Tafea, Sanma and Shefa provinces accompanied integrated MDA. Dried blood spots (DBS) from randomly selected participants aged ≥1 year were tested by multiplex bead assay for IgG against Pgp3 (trachoma), Bm14 and Wb123 (LF), and rp17 and TmpA (yaws). Village-clustered seroprevalence was estimated by province and island in children aged 1–9 (trachoma, LF) and 1–14 years (yaws).Findings: Of 2,804 village-matched DBS, 2,738 had recorded age. In children aged 1–9 years, anti-Pgp3 seroprevalence on Tanna (Tafea) rose from 5·3% (2021) to 31·8% (2023); provincial seroconversion rates were 2·8–3·7 per 100 person-years. Provincial anti-Bm14 seroprevalence was ≤1·1% (island-level maximum 2·6%), whereas island-level anti-Wb123 reached 31·8% (Tanna) and 21·7% (Efate); no double-positives occurred in this age group. Twenty-one children aged 1–14 years were yaws seropositive (anti-rp17/anti-TmpA double-positive): 17 in Tafea (all Tanna) and four in Shefa (all Efate).Interpretation: Integrated multiplex serosurveillance generated concurrent data for three NTDs from a single DBS within routine programme activities, a first for Vanuatu. Findings support continued post-validation surveillance for trachoma and LF, identify Tafea as a yaws focus, and offer a replicable model for resource-limited settings.